BGB-A317-290-LTE1
Enrolling by invitation
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Study Overview
Sex:
All 
Age: 18 Years / N/A
No Study Documents
Locations
Study Overview
Sex:
All
Age: 18 Years / N/A
No Study Documents